Roche autoimmune disease drug disappoints in closely watched trial
Bio Pharma Dive
MARCH 21, 2024
Though the medicine hit its goal in a Phase 3 study in myasthenia gravis, the results fell short of expectations in a boost to rival drug developers like Argenx and AstraZeneca.
Let's personalize your content